Clinical Trial Update: High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment [Phase 4]

View source ↗

Summary

Phase 4 study evaluating a high relaxivity contrast agent for cardiac MRI to assess myocardial scar in patients with myocardial fibrosis; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Fibrosis

Drugs mentioned

• High Relaxivity Contrast Agent for Cardiac MR in Myocardial Scar Assessment

Snippet

Sponsor: Johns Hopkins University | Conditions: Myocardial Fibrosis | Phase 4 | Status: RECRUITING